Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

61,154

Income (loss) from operations (6,076) 2,927 (25,237) (33,571)

Other income (expense)

Interest income (expense) 419 (32) 429 (982)

Change in fair value of

warrants 41 - 1,750 -

Other income (expense), net 1,817 500 2,932 561

Net income (loss) attributable

to common stockholders $(3,799) $3,395 $(20,126) $(33,992)

Basic net income (loss) per

common share $(0.09) $0.11 $(0.55) $(1.29)

Diluted net income (loss) per

common share $(0.09) $0.11 $(0.55) $(1.29)

Weighted average shares used

to compute basic diluted net

income (loss) per share 40,757 31,416 36,362 26,366

Weighted average shares used to

compute diluted net income

(loss) per share 40,757 31,966 36,362 26,366


'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3